Introduction {#S1}
============

Type 1 diabetes mellitus (T1DM) is a multisystem disease with both biochemical and anatomical/structural consequences. It is a chronic disease of carbohydrate, fat, and protein metabolism caused by the lack of insulin, which results from the marked and progressive inability of the pancreas to secrete insulin because of autoimmune destruction of the β cells \[[@ref1]\].

T1DM can occur at any age. It occurs most commonly in juveniles but can also occur in adults, especially in those in their late 30s and early 40s \[[@ref2]\].

Diabetic complications can be classified broadly as microvascular or macrovascular disease. Microvascular complications include neuropathy (nerve damage), nephropathy (kidney disease), and vision disorders (e.g. retinopathy, glaucoma, cataract, and corneal disease). Macrovascular complications include heart disease, stroke, and peripheral vascular disease (which can lead to ulcers, gangrene, and amputation). Other complications of diabetes include infections, metabolic difficulties, impotence, autonomic neuropathy, and pregnancy problems \[[@ref1]\].

Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus, greatly affecting the life quality and survival of the patients. Regarding global prevalence, the number of patients with diabetic nephropathy is increasing day by day \[[@ref3]\]. The natural history of diabetic nephropathy is one of clinical silence for years to decades, during which time serious underlying renal lesions may be developing. Once the clinical manifestations, including the development of persistent microalbuminuria, are present the structural injury is often far advanced. Because interventions at these late stages of disease may only slow but not completely arrest the inexorable progression towards renal failure, understanding early natural history becomes important \[[@ref4]\].

Diabetic nephropathy, one of the leading causes of end-stage renal disease, affects 20% to 30% patients with T1DM. The course of diabetic nephropathy is slow. An increased urinary albumin excretion rate of 30 to 300 mg/day (microalbuminuria) constitutes an early stage of nephropathy, especially when it becomes persistent (at least two of three consecutive urine samples. Annual screening for microalbuminuria should be initiated once the child is 10 years of age and has had diabetes for 5 years; more frequent testing is indicated if values are increasing \[[@ref5]\].

Screening for subclinical retinopathy, neuropathy, and nephropathy should be started at puberty and at least three years after the diabetes diagnosis with the goal of detecting early abnormalities responsible for subclinical disorders that can be reversed by improved metabolic control, thus preventing the occurrence of irreversible, potentially incapacitating lesions \[[@ref6]\].

The association of well-established risk markers and promoters of renal injury, including the degree and tracking of albuminuria, glycaemic control, blood pressure changes, incipient retinopathy and genetic nephropathy, and the decision to start pharmacological intervention \[[@ref7]\].

Increased urinary protein excretion in patients with diabetes has long been known to predict increased mortality, and its absence is associated with near-normal life expectancy. Recent studies confirmed and extended these findings by illustrating the progressive increase in mortality by degree of albuminuria. The excess mortality is due primarily to end-stage renal disease and to cardiovascular disease, which share many risk factor \[[@ref8]\].

Urinary excretion of lower molecular weight proteins such as *N*-acetyl-β-glucosaminidase (β-NAG) and retinol binding protein (RBP), α1-microglobulin, and transferrin (TRF) \[[@ref9]\] indicate proximal tubular dysfunction and may identify diabetic patients at risk of developing diabetic nephropathy and may indicate the onset of microalbuminuria \[[@ref10]\]. Also, plasma total homocysteine rises with increased urinary albumin excretion in diabetes \[[@ref11]\].

The present study was planned to follow diabetic patients who were normoalbuminuric but had increased levels of other nephropathy markers, namely (plasma homocysteine, urinary *n*-acetyl-β-glucosaminidase, transferrin, α1-microglobulin, retinol binding protein) to ascertain the following: the lag period to develop microalbuminuria and the determinants of conversion to microalbuminuria.

Material and methods {#S2}
====================

Subjects {#S2_1}
--------

This study is a follow-up for el Salem *et al*., 2002. It included 35 type I diabetic children and adolescents recruited from regular attendees of the Diabetology Specialised Clinic, Children's Hospital, Ain Shams University, with previously measured urinary *N*-acetyl-β-glucosaminidase (13) or homocysteine (11) or transferrin (28) or α1-microglobulin (27) or retinol binding protein (13), as an early predictor of diabetic nephropathy in T1DM.

The study was a retrospective study including 35 patients with type I diabetes mellitus recruited from regular attendees of the Diabetes Clinic, Children's hospital, Ain Shams University during the period from October 1, 2011 to April 30, 2012.

Of the 35 diabetic patients who were enrolled, 24 patients were normoalbuminuric at baseline \[[@ref9]\]. These patients were tested for markers other than urinary microalbumin, to predict diabetic nephropathy and early renal impairment in children and adolescents with T1DM by detection of the progression of microalbuminuria in children and adolescents without microalbuminuria. These markers are: α1-microglobulin, transferrin, RBP, NAG, and homocysteine.

They were 24 normoalbuminuric patients: 12 (50%) males and 12 (50%) females, their ages ranged from 12 to 33 years, with a mean age of 15.176 ±4.878 years, and disease duration ranging from 3 to 17 years with a mean of 7.9 ±3.3 years.

Five years or less from the onset of diabetes (end point), six patients turned microalbuminuric, whereas 18 developed excess microalbumin in urine after 5 years. Accordingly, sensitivity and specificity of urinary and plasma markers of diabetic nephropathy (DN) were calculated.

Arbitrarily, patients were divided into two groups according to level of urinary microalbumin: whether equal to or below 60 mg/dl (double the normal level of microalbuminuria (MA)) or above it. The two groups were compared with no significant difference in any parameter included.

They were divided according to positivity of markers of nephropathy: Urinary NAG: 10 patients T1DM without microalbuminuria with previously estimated NAG marker. Three of them had high level of NAG and seven had normal level of NAG.Urinary transferrin: 18 T1DM patients without microalbuminuria with previously estimated transferrin marker. All of them had high levels of transferrin.Urinary α1-microglobulin: 17 T1DM patients without microalbuminuria with previously estimated α1 microglobulin marker. Fourteen of them had high levels of α1-microglobulin and 3 patients had normal levels of α1-microglobulin.Urinary RBP: 10 T1DM patients without microalbuminuria with previously estimated RBP marker. Eight of them had high levels of RBP, and two patients had normal levels of RBP.Plasma homocysteine: 11 T1DM patients without microalbuminuria with previously estimated homocysteine marker. Three of them had high levels of homocysteine, and 8 patients had normal levels of homocysteine.

Methods {#S2_2}
-------

All the files of the patients were revised for the following: Full medical history taking after informing them about the study and obtaining their consent to participate, laying stress on the following: Age of the patient at the time of the study.Age at the onset of diabetes.Duration of diabetes.Symptoms suggesting diabetic complications: -- Symptoms of hypertension as persistent headache.-- Swelling, tingling, and numbness of lower limbs.-- Urinary symptoms suggestive of urinary tract infection such as dysuria, frequency, and loin pain.Dose of insulin therapy calculated in (U/kg/day) during the year prior to the study.Thorough clinical examination laying stress on:

Blood pressure, measured by conventional mercurial sphygmomanometer, and hypertension defined as the median value more than the 95^th^ percentile of at least three independent measurements \[[@ref12]\].

Anthropometry including: Height in meters by using a standard stadiometer.Weight in kg by using a mechanical column scale.Body mass index (BMI) calculated as percentage of: weight (kg)/height (m^2^).Height and weight were expressed as percentile values.Full neurological examination to detect peripheral neuropathy.Fundus examination, to detect retinopathy by direct ophthalmoscopy.

Laboratory investigations: Glycosylated haemoglobin (HbA~1c~) by high-performance liquid chromatography using the Bio-Rad haemoglobin testing system, D-10 Dual Program \[[@ref13]\].Microalbumin in urine: Urinary albumin excretion was measured using immune turbidimetric methods. It was used to assess the presence of nephropathy. Patients initially detected as having a urinary albumin excretion rate (AER) \> 30 μg/mg creatinine were asked to perform three further urine collections at intervals of 3--6 months. Persistent microalbuminuria was defined when two of three samples showed an excretion rate of 30--300 μg/mg creatinine \[[@ref14]\].

Serum cholesterol and serum triglycerides (TG): Total cholesterol was assayed on a Synchron CX-9 system autoanalyser using the cholesterol esterase reaction applying a timed end-point method \[[@ref15]\].Triglycerides assay was done on a Synchron CX-9 autoanalyser using the lipase reaction applying a timed endpoint method \[[@ref16]\].

Normal laboratory values of nephropathy markers: urinary NAG (5.95 U/gm), RBP (270 mg/dl), transferrin (0.06 mg/mmol), α1-microglobulin (0.6 mg/mmol), and plasma homocysteine (15 mmol/l), by ELISA technique \[[@ref9]\].

Statistical analysis {#S2_3}
--------------------

Analysis of data was done by IBM computer using SPSS (statistical program for social science version 15.0) (SPSS Inc., Chicago, IL, USA) for Windows^®^, as follows: description of quantitative variables as mean, SD, and range, description of qualitative variables as number and percentage and χ^2^ test was used to compare qualitative variables between groups. Fisher's exact test was used instead of χ^2^ when one expected cell or more was less than 5. Unpaired *t*-test was used to compare two groups regarding quantitative variables. Paired *t*-test was used to compare quantitative variables in the same group.

One-way ANOVA test (analysis of variance) was used to compare more than two groups as regard quantitative variables. The Kruskal-Wallis test was used instead of one-way ANOVA for non-parametric data. Spearman's correlation test was used to rank different variables positively or inversely. Receiver operator characteristic curve (ROC) was used to find out the best cut of value and validity of certain variable. *P*-values \> 0.05 were considered insignificant, *p* \< 0.05 significant, and *p* \< 0.01 highly significant.

Results {#S3}
=======

Out of the 35 diabetics who were enrolled, 24 were normoalbuminuric. [Table I](#T1){ref-type="table"} describes clinical data of patients at baseline study ([Figure 1](#F1){ref-type="fig"}). Patients at baseline were tested for markers other than microalbuminuria in urine to predict diabetic nephropathy, as shown in [Table II](#T2){ref-type="table"}. Patients were re-assessed at the time of study, and their clinical data are shown in [Table III](#T3){ref-type="table"}.

![Outcomes of the 35 enrolled patients](AMS-AD-4-39505-g001){#F1}

###### 

Descriptive data of 24 diabetics with normoalbuminuria at baseline study

  Parameter                  Mean ± SD (range)
  -------------------------- -------------------
  Age \[years\]              12.7 ±4.4 (4--19)
  Duration of DM \[years\]   3.8 ±3.5 (1--15)
  Height (%)                 70 ±22.3 (25--97)
  Weight (%)                 71.5 ±20 (25--97)
  SBP (%c)                   61 ±13.6 (50--90)
  DBP (%)                    61 ±13.6 (50--90)
  HbA~1c~ (%)                8.3 ±2.9 (5--15)

###### 

Distribution of normoalbuminuric diabetics by markers at baseline

  Item                                  Normal, *n* (%)   High, *n* (%)   Total, *n* (%)
  ------------------------------------- ----------------- --------------- ----------------
  Urinary NAG \[U/gm\]                  7 (70)            3 (30)          10 (100)
  Urinary RBP \[mg/dl\]                 2 (20)            8 (80)          10 (100)
  Urinary α-microglobulin \[mg/mmol\]   3 (30)            14 (82)         17 (100)
  Urinary transferrin \[mg/mmol\]       0 (0)             18 (100)        18 (100)
  Plasma homocysteine \[mmol/l\]        8 (80)            3 (27)          11 (100)

###### 

Descriptive data of 24 diabetic patients at the time of study

  Parameter                  Mean ± SD     Range
  -------------------------- ------------- ----------
  Age \[years\]              25.2 ±4.9     12--33
  Duration of DM \[years\]   14.4 ±7.6     1--25
  Weight (%)                 81.9 ±14.7    50--97
  Height (%)                 83.7 ±14.6    50--95
  BMI \[kg/m^2^\]            31.6 ±6.1     20--40
  SBP (%)                    87.9 ±10.8    50--95
  DBP (%)                    72.8 ±18.1    50--90
  HbA~1c~ (%)                12.6 ±3.3     8--19
  Cholesterol \[mg/dl\]      267.2 ±72     140--399
  Triglyceride \[mg/dl\]     144.4 ±50.6   56--210

[Table IV](#T4){ref-type="table"} and [Figure 2](#F2){ref-type="fig"} show that with increasing duration, mean growth pattern percentiles declined.

###### 

Comparison between diabetics at the time of the study versus at baseline study

  ----------------------------------------------------------------------------------------
  Parameter            At study\    Baseline\    Difference\    Paired t-test   
                       Mean ± SD    Mean ± SD    Mean ± SD                      
  -------------------- ------------ ------------ -------------- --------------- ----------
  Age \[years\]        25.2 ±4.9    12.7 ±4.4    12.5 ±3.5      17.5            \< 0.001

  Duration \[years\]   13.4 ±5.1    3.8 ±3.5     9.6 ±4.5       10.4            \< 0.001

  Weight (%)           50.8 ±25.4   71.5 ±19.9   --20.7 ±23.1   --4.4           \< 0.001

  Height (%)           50.5 ±30.1   69.9 ±22.3   --19.4 ±31.4   --3.1           0.006

  SBP (%)              82.4 ±11.4   61.1 ±13.7   21.4 ±17.1     6.1             \< 0.001

  DBP (%)              78.5 ±12.2   61.1 ±13.7   17.5 ±19.1     4.5             \< 0.001

  HbA~1c~ (%)          10.9 ±2.7    8.3 ±2.9     2.6 ±3.1       3.7             0.001
  ----------------------------------------------------------------------------------------

![Clinical and laboratory parameters of diabetic patients at baseline study and at the time of the study](AMS-AD-4-39505-g002){#F2}

At time of study, all patients turned to be microalbuminuric with variable onset and hence with duration as shown in [Table V](#T5){ref-type="table"}.

###### 

Onset and duration of MA in the studied diabetes

  Parameter                      Mean ± SD   Range
  ------------------------------ ----------- -------
  Age at onset of MA \[years\]   16.6 ±3.4   8--22
  Duration of MA \[years\]       7.9 ±3.3    3--17

Arbitrarily, patients were divided into two groups according to the level of urinary microalbumin: equal to or below 60 mg/dl (double the normal level of MA) or above it. Patient groups were compared in [Table VI](#T6){ref-type="table"}, with no significant difference in any parameter included ([Figures 3](#F3){ref-type="fig"}--[5](#F5){ref-type="fig"}).

###### 

Comparison between diabetics with high MA regarding their clinical and laboratory parameters

  Parameter                MA            *T*-test              
  ------------------------ ------------- ------------- ------- ------
  Age of onset \[years\]   12.9 ±4.3     11.5 ±2.5     0.7     0.39
  Weight (%)               49.5 ±23.2    53.0 ±30.2    --0.3   0.75
  Height (%)               44.2 ±27.1    61.1 ±33.5    --1.3   0.18
  BMI \[kg/m^2^\]          19.1 ±3.8     19.1 ±2.5     --0.6   0.55
  SBP (%)                  79.9 ±13.1    86.7 ±6.6     --1.4   0.16
  DBP (%)                  76.0 ±13.6    82.8 ±8.3     --1.3   0.19
  HbA~1c~ (%)              10.8 ±2.4     11.1 ±3.2     --0.2   0.79
  Cholesterol \[mg/dl\]    178.4 ±34.6   185.5 ±44.4   --0.4   0.66
  Triglyceride \[mg/dl\]   80.9 ±30.4    99.8 ±38.6    --1.3   0.19

![Clinical parameter of microalbuminurics with respect to MA level](AMS-AD-4-39505-g003){#F3}

![Clinical parameter of microalbuminurics with respect to MA level](AMS-AD-4-39505-g004){#F4}

![Laboratory parameter of microalbuminurics with respect to MA level](AMS-AD-4-39505-g005){#F5}

Patients were distributed according to onset of MA and number of positive markers of MA into two groups as shown in [Table VII](#T7){ref-type="table"} ([Figures 6](#F6){ref-type="fig"}--[10](#F10){ref-type="fig"}).

###### 

Correlation between studied markers and lab values

  Parameter          Microalbuminuria at the baseline study   Microalbuminuria at follow-up             
  ------------------ ---------------------------------------- ------------------------------- --------- ---------
  NAG                0.418                                    0.726                           0.321     0.285
  RBP                0.839                                    0.367                           --0.378   0.203
  α1-microglobulin   --0.234                                  0.514                           --0.078   0.699
  Age                0.544                                    0.084                           --0.027   0.881
  Duration           0.137                                    0.688                           0.331     0.056\*
  BMI                --0.172                                  0.613                           0.133     0.453
  HBA~1c~            --0.021                                  0.951                           0.318     0.067
  Cholesterol        0.222                                    0.512                           0.272     0.119
  Triglyceride       --0.027                                  0.938                           --0.066   0.709
  Transferrin        --0.602                                  0.050\*                         0.159     0.368

![ROC curve to define the best cut-off α1-microglobulin (mg/l) to detect microalbuminuria. Urinary α1-microglobulin (mg/l) was a valid marker for microalbuminuria. The optimum cut-off value was 1.8 mg/l, with a sensitivity of 50%, specificity 82.4%, positive predictive value (PPV) 55.6%, and negative predictive value (NPV) 100% with a diagnostic accuracy of 0.63%](AMS-AD-4-39505-g006){#F6}

![ROC curve to define the best cut-off. Retinol binding protein in mg/l to detect microalbuminuria. Urinary retinol binding protein (mg/l) was a moderately valid marker for microalbuminuria. P \< 0.0001 and area under the curve (AUC) was 99%. The best cut-off value was \< 400 mg/l, with a sensitivity of 100%, specificity 50%, PPV 62%, NPV 73%, and diagnostic accuracy of 0.68%](AMS-AD-4-39505-g007){#F7}

![ROC curve to define the best cut-off transferrin (mg/l) to detect microalbuminuria. Urinary transferring (mg/l) was a moderately valid marker for microalbuminuria. The best cut-off value was 10 mg/l, with a sensitivity of 50%, specificity 77%, PPV 55.6%, NPV 73%, and diagnostic accuracy of 0.533%](AMS-AD-4-39505-g008){#F8}

![ROC curve to define the best cut-off urinary NAG (mg/l) to detect microalbuminuria. Urinary NAG (mg/l) is a valid marker for microalbuminuria p \< 0.0001 and AUC was 99%. The best cut-off value was \< 4.3 mg/l, with a sensitivity of 60%, specificity 75%, PPV 60%, NPV 75%, and diagnostic accuracy of 0.58%](AMS-AD-4-39505-g009){#F9}

![ROC curve to define the best cut-off homocysteine (mg/l) to detect microalbuminuria. Urinary homocysteine (in mg/L) was reliable in the prediction of microalbuminuria. The best cut-off value was 17.1 mg/l, with a sensitivity of 18.2%, specificity 100%, PPV 100%, NPV 72.7%, and diagnostic accuracy of 0.55%](AMS-AD-4-39505-g010){#F10}

Discussion {#S4}
==========

T1DM results from the autoimmune destruction of insulin-producing β-cells of the pancreas. Genetic and, as yet undefined, environmental factors act together to precipitate the disease. The excess mortality associated with the complications of T1DM and the increasing incidence of childhood T1DM emphasise the importance of therapeutic strategies to prevent this chronic disorder \[[@ref17]\].

This study is a follow-up of 35 diabetic patients from the previous study of Salem *et al*. \[[@ref9]\] as a baseline to our study. These patients were with previously measured five markers: α1-microglobulin, transferrin, retinol binding protein, homocysteine, *N* acetyl glutaminase, and early renal impairment in children and adolescents with T1DM by detection of the progression of microalbuminuria in children and adolescents with microalbuminuria and those without.

It is a pioneer study in Egypt to measure these markers, and it was the baseline of our study to investigate the role of these marker in the prediction of microalbuminuria.

Diabetic nephropathy is a kidney disease that occurs as a result of diabetes. Cardiovascular and renal complications share common risk factors such as blood pressure, blood lipids, and glycaemic control. Thus, chronic kidney disease can predict cardiovascular disease in the general population. The impact of diabetes on renal impairment changes with increasing age. Serum markers of glomerular filtration rate and microalbuminuria identify renal impairment in different segments of the diabetic population, indicating that serum markers as well as microalbuminuria tests should be used in screening for nephropathy in diabetic people \[[@ref18]\].

In our study there was correlation between microalbuminuria and the duration of diabetes. This is in accord with Chowta *et al*. \[[@ref19]\], who showed that the Incidence of microalbuminuria increases with age as well as with increased duration of diabetes mellitus. Earlier studies have shown positive correlation of microalbuminuria with the age of patients \[[@ref20]\]. In our study there was no statistically significant age difference in the diabetic patients with and without microalbuminuria.

Our study showed insignificant sex difference, and there was no significant difference in BMI between diabetic patients with or without microalbuminuria. This is in accord with Chowta *et al*. \[[@ref19]\], who found that there was no effect of BMI and sex on the prevalence of microalbuminuria .

Our study included diabetic patients with positive microalbuminuria and systolic and diastolic blood pressure \> 95^th^ percentile, but 11 of them had blood pressure \< 95^th^ percentile because they were controlled by ACEI. This is in accordance with Gallego *et al*. \[[@ref21]\] and Marcovecchio *et al*. \[[@ref22]\] showing that that elevated blood pressure is a common finding in people with T1DM, and it has been associated with the risk of developing microvascular complications. In our study, patients with microalbuminuria had higher frequency of hypertension, with a statistically significant difference.

Among those with T1DM, the incidence of hypertension rises from 5% at 10 years, to 33% at 20 years, and 70% at 40 years. There is a close relationship between the prevalence of hypertension and increasing albuminuria. Blood pressure typically begins to rise within the normal range or within a few years after the onset of microalbuminuria and increases progressively as the renal disease progresses \[[@ref23]\].

In our study, patients with microalbuminuria had higher frequency of complications, with a statistically significant difference in diabetics with positive microalbuminuria. It is either an acute complication (hypoglycaemia, diabetic ketoacidosis) or a chronic complication (microvascular complications such as retinopathy or neuropathy, and macrovascular complications such as coronary artery disease, cerebrovascular disease, peripheral vascular disease).

Girach and Vignati \[[@ref24]\] showed that significant associations have been reported between the different microvascular complications of diabetes, so that patients with one complication often develop a second one, suggesting common risk factors and/or pathogenetic mechanisms.

We found that there was a significant correlation between serum cholesterol and serum triglyceride and microalbuminuria in diabetic patients. This is in accordance with other studies that show that chronic renal disease is accompanied by characteristic abnormalities of lipid metabolism are reflected in elevated plasma lipid levels \[[@ref25]\].

In addition, Katakami *et al*. \[[@ref26]\], in parallel to our study, showed that triglyceride levels were significantly higher in patients with T1DM compared to non-diabetic individuals (*p* \< 0.05).

Our results disagree with those of Singh *et al*. \[[@ref27]\] and Oz Gul *et al*. \[[@ref28]\], who demonstrated that there was no difference in total cholesterol and triglycerides between diabetics with and without microalbuminuria.

There was no statistically significant difference between both groups regarding HbA~1c~ (*p* = 0.108), and this disagrees with the results of

Hovind *et al*. \[[@ref1]\], who stated that increased HbA~1c~ as a marker of chronic hyperglycaemia is the most established and unquestioned risk factor for diabetic kidney disease in adult and paediatric T1DM, with *p* \< 0.001. This study included 286 participants, of whom 216 were adults.

Raile *et al*. \[[@ref29]\] found that microalbuminuria was associated with this study included 27,805 children, adolescents, and adults with T1DM. One of limitation of our study was the small cohort.

This study evaluated the correlation between previously measured markers: α1-microglobulin, transferrin, retinol binding protein, homocysteine, N acetyl glutaminase, and early renal impairment in children and adolescents with T1DM, by detection of the progression of microalbuminuria in children and adolescents with microalbuminuria and those without, in the study done by Salem *et al*. \[[@ref9]\]. We considered these markers as the baseline markers because this was a retrospective study of the same patients.

The ability to detect early and probably reversible renal injury using relatively inexpensive, non-invasive, and reliable biomarkers should lead to better care. Diabetic tubulointerstitial injury is a feature of early diabetic nephropathy and an important predictor of future renal dysfunction. Before the onset of gross structural changes in the renal tubules, lysosomal enzymes like NAG have been found to be markedly increased in urine. NAG marker is a significant marker (with mean ± SD of 9.9933 ±3.7 and a *p*-value of 0.011). It is a valid marker with 60% sensitivity and 75% specificity. Several studies elsewhere have shown increased urinary excretion of NAG in diabetics.

The results of our study confirm and extend the previous observations in small selected groups of patients with diabetes as in the baseline study of Salem *et al*. \[[@ref9]\]. Our study included 13 patients with previously estimated NAG marker. Six of them had high levels of NAG and seven had normal levels of NAG. Three of the patients with high levels of NAG were positive for microalbuminuria and were still microalbuminuric, and the other three patients with high levels of NAG with negative microalbuminuria also developed microalbuminuria.

Salem *et al*. \[[@ref9]\] showed that diabetic nephropathy (DN) is usually characterised by glomerular dysfunction, with microalbuminuria as an early indicator. Urinary excretion of lower molecular weight proteins such as β-NAG with mean ± SD 6.88 ±3.76 (*p* \< 0.001) and RBP with mean ± SD 386.6 ±151.8 (*p* \< 0.001) indicate proximal tubular dysfunction and may identify diabetic patients at risk of developing diabetic nephropathy.

This goes hand in hand with Vaidya *et al*. \[[@ref30]\], who showed that low urinary levels of NAG are associated with regression of microalbuminuria in T1DM, suggesting that tubular dysfunction is a critical component of the early course of DN. One of the limitations of the study by Vaidya *et al*. \[[@ref30]\] is the small number of patients who had microalbuminuria progression, thereby preventing adequate evaluation of biomarkers associated with microalbuminuria progression. Although I agree with Vaidya *et al*. \[[@ref30]\], one of the advantages of our study is that we followed up the patients for 10 years whereas Vaidya *et al*. \[[@ref30]\] followed up only for 2 years, which is too short to adequately determine the potential of urinary NAG to predict permanent regression or progression of microalbuminuria.

Another significant marker is transferrin (with mean ± SD of 12.273 ±6.405). It is a valid marker with moderate sensitivity of 50% and specificity of 77%. Our study included 28 patients with previously estimated transferrin marker. All of them had high levels of transferrin; 10 patients with high levels of transferrin were positive for microalbuminuria and were still microalbuminuric, and the other 18 patients with high levels of transferrin and with negative microalbuminuria also developed microalbuminuria.

Transferrin is synthesised in liver. It carries less negative charge than microalbuminuria. When the glomerular charge barrier is impaired, transferrin will run into urine more easily than microalbuminuria. Transferrin is a sensitive indicator for glomerular charge barrier damage. When renal glomeruli are impaired, elevation of transferrin excretion occurs earlier than microalbuminuria.

The concentration of urine transferrin is lower than that of albumin. It may be degraded much more easily than albumin. Albuminuria and transferrin should be combined in early diagnosis of diabetic nephropathy \[[@ref31]\].

Another significant marker is serum homocysteine level (with mean ± SD of 1.33 ±3.95 SD and *p* \< 0.001). It is a highly valid marker with 18% sensitivity and 100% specificity. Our study included 17 patients with previously estimated homocysteine marker. Seven of them had high levels of homocysteine, and 10 patients had normal levels of homocysteine. Three patients with high levels of homocysteine were positive for microalbuminuria and were still microalbuminuric, and the other four patients with high levels of homocysteine with negative microalbuminuria also developed microalbuminuria.

This agrees with the results of Stühlinger *et al*. \[[@ref32]\], which showed that overt nephropathy is associated with elevations of plasma homocysteine in patients with diabetes, with a *p* \< 0.05.

Retinol binding protein (RBP) marker and α1-microglobulin marker are insignificant in the prediction of diabetic nephropathy.

RBP was with mean ± SD of 44.2 ±72.7 and *p* = 0.20. RBP is a valid marker with 100% sensitivity and 50% specificity. Our study included 13 patients with previously estimated RBP marker. Eleven of them had high levels of RBP, and two patients had normal levels of RBP. Three patients with high levels of RBP were positive for microalbuminuria and still microalbuminuric, and the other 8 patients with high levels of RBP and with negative microalbuminuria also developed microalbuminuria.

α1-microglobulin was with mean ± SD of 4.86 ±3.7 and *p* of 0.169. α1-microglobulin is a valid marker with 50% sensitivity and 82% specificity. Our study included 27 patients with previously estimated α1-microglobulin. Twenty-two of them had high levels of α1-microglobulin, and five patients had normal levels of α1-microglobulin. Eight patients with high levels of α1-microglobulin were positive for microalbuminuria and were still microalbuminuric, and of the other 14 patients with high levels of α1-microglobulin who were negative for microalbuminuria, only 10 developed microalbuminuria.

This does not agree with Ching *et al*. \[[@ref33]\], who showed that α1-microglobulin has been studied as a marker for renal tubular dysfunction before. Due to its stability at low pH, its use has been suggested in screening for tubular abnormalities. Increased excretion of α1-microglobulin was found in the early course, while albumin excretion was still within normal range in the urine of type I patients. Non-correlation of albuminuria with α1-microglobulin excretion in T1DM may indicate whether the kidney impairment is severe or diffuse. Although urinary α1-microglobulin and albumin are related, in early nephropathy one may be present in the absence of the other. Hence, in addition to urinary albumin (which mainly measures glomerular function), urinary α1-microglobulin (which measures proximal tubular function) is useful for the early detection and monitoring of renal disease in diabetic subjects.

Gandhi *et al*. \[[@ref34]\] also agreed with our study and showed that although microalbuminuria has been proposed as an early predictive biomarker of DN, it is clear that in the majority of patients it can regress to normoalbuminuria and in a minority it progresses to proteinuria.

This agrees with Matheson *et al*. \[[@ref35]\], who provided a synopsis of urinary biomarkers that potentially provide a basis for the development of improved diagnostic tests. Three main pathways for the sourcing of potential makers have been identified: kidney damage, oxidative stress, and low-grade inflammation including atherosclerosis and vascular damage. This review briefly presents some of the most relevant urinary biomarkers that may be used to monitor the development or progression of diabetes and its complications. In particular, biomarkers of renal dysfunction such as transferrin and *N*-acetyl-β-D-glucosaminidase might prove to be better than urinary albumin, the current gold standard, in the detection of incipient nephropathy and risk assessment of cardiovascular disease.

Regarding the predictability of urinary markers, urinary NAG is the most predictable marker with both high sensitivity and specificity, and with a sensitivity of 60%, specificity 75%, PPV 60%, NPV 75%, and diagnostic accuracy of 0.58%. Urinary RBP is another marker with low sensitivity but high specificity. Urinary α1-microglobulin is a valid marker with high sensitivity but low specificity. Contrary to previous markers, plasma homocysteine has a high specificity but low sensitivity.

It should also be noted that all of the previously mentioned markers are now easily available and cheap to perform in most laboratories and clinical pathology laboratories in Egypt and all around the world, hinting clearly at their cost effectiveness in early detection of diabetic micro albuminuria and diabetic nephropathies.
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